Cassandra Protocol
02 October 2026. The Q4 archives open on Natera and the brittle architecture of precision oncology. We dissect the miracle of early cancer detection against the crumbling infrastructure of healthcare reimbursement. Step into the cold and press play.
Natera
Natera is selling a subscription model for survival, but the financial architecture is bleeding. An analysis of the reimbursement void in precision oncology and the corporate mirage of standard-of-care diagnostics.
Natera
An audit of Natera's Signatera assay and the structural realities of precision oncology. Examining the clinical infrastructure of molecular residual disease detection versus the limitations of healthcare reimbursement models.